Fennec Pharmaceuticals Inc. (FENC)

NASDAQ: FENC · USD

$10.5

-0.09 (-0.8%)· Recorded snapshot

Market cap	369.3M
Revenue (ttm)	59.2M
Net income (ttm)	-3.3M
EPS (ttm)	-$0.10
Shares out	35.1M
P/E (forward)	17.5x
Volume	106,768
Beta	1.23

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 59.2M
Net income (ttm): -3.3M
EPS (ttm): -$0.10
P/E (forward): 17.5x
Market cap: 369.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E17.5

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-18.6

P25 n/aP50 n/aP75 n/a

ROIC-2.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All FENC indicators

Market & fundamental data

Available fields

218

Groups with data

Currency

USD

Showing 218 of 218 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001211583
Company name	Fennec Pharmaceuticals Inc.
Country	United States
Country code	US
CUSIP number	31447P100
Earnings date	2026-11-12
Earnings time	amc
Employees	35
Employees change	3
Employees growth	9.38%
Enterprise value	$328M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1996
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2001-06-05
Is primary listing	Yes
Is SPAC	No
ISIN number	CA31447P1009
Last 10-K release date	2026-03-27
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split date	2014-09-05
Last stock split type	Reverse
Market cap	$369.3M
Market cap category	Small-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$10.53
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	FENC
U.S. state	North Carolina
Website	https://www.fennecpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-0.96%
EV/Sales	5.46x
FCF / EV yield	-0.63%
FCF yield	-0.56%
Forward EV/Sales	3.74x
Forward P/E	17.51x
Forward P/S	4.22x
P/B ratio	8.77x
P/S ratio	6.15x
Price / tangible book value	8.58x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-1.9%
EBITDA margin	-1.72%
Gross margin	93.73%
Operating margin	-1.9%
Pretax margin	-5.24%
Profit margin	-5.49%
Profit per employee	$-92,857
Profitable quarters	2
Revenue per employee	$1.7M
ROA	-1.16%
ROA (5Y)	-25.84%
ROCE	-1.77%
ROE	-18.58%
ROIC	-2.59%
SBC / revenue	12.67%
Tax / revenue	0.25%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (QoQ)	754.26%
EPS growth quarters	2
EPS growth years	0
Gross profit growth	85.42%
Gross profit growth (Q)	97.5%
Gross profit growth 3Y	107.55%
Gross profit growth 5Y	218.26%
Net income growth (QoQ)	881.59%
Net income growth quarters	2
Net income growth years	0
OCF growth (QoQ)	-97.9%
Revenue growth	77.83%
Revenue growth (Q)	85.18%
Revenue growth (QoQ)	18.31%
Revenue growth 3Y	108.46%
Revenue growth 5Y	222.41%
Revenue growth quarters	5
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$102,667
EBIT	$-1.1M
EBITDA	$-1M
EPS	$-0.10
FCF per share	$-0.06
Financing cash flow	$24.6M
Free cash flow	$-2M
Free cash flow minus SBC	$-9.5M
Gross profit	$55.5M
Income taxes	$148,000
Net borrowing	$-19.5M
Net cash flow	$22.5M
Net income	$-3.3M
Operating cash flow minus SBC	$-9.5M
Operating income	$-1.1M
Revenue	$59.2M
Stock-based compensation	$7.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.16
Book value per share	$1.21
Debt / equity	0
Interest coverage	-1.19
Long-term assets	$3.3M
Long-term liabilities	$20.9M
Net cash (debt)	$41.2M
Net cash / market cap	11.32%
Net debt / equity	-0.97
Piotroski F-Score	4
Shareholders' equity	$42.4M
Tangible book value	$42.4M
Tangible book value per share	$1.21
Total assets	$75.8M
Total cash	$41.2M
Total debt	$0
Total liabilities	$33.3M
WACC	11.01%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.98
Current assets	$72.5M
Current liabilities	$12.4M
Current ratio	5.85
Inventory turnover	1.62
Net working capital	$18.9M
Quick ratio	5.21
Working capital	$60.1M
Working capital turnover	1.28

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-16.69%
Dividend yield	0%
Shareholder yield	-16.69%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	451.89%
10Y return CAGR	18.63%
10Y total return	451.97%
150-day SMA	$9.61
15Y price change	612.45%
15Y return CAGR	13.98%
15Y total return	612.4%
1D price change	-0.85%
1M price change	-0.71%
1M total return	-0.71%
1W price change	1.45%
1W total return	1.45%
1Y price change	19.39%
1Y return CAGR	19.4%
1Y total return	19.39%
20-day SMA	$10.36
200-day SMA	$9.17
20Y price change	-42.65%
20Y return CAGR	-2.74%
20Y total return	-42.65%
3M price change	3.13%
3M total return	3.13%
3Y price change	53.95%
3Y return CAGR	15.46%
3Y total return	53.95%
50-day SMA	$10.97
50-day SMA vs 200-day SMA	50over200
52-week high	$13.25
52-week high date	2026-08-12
52-week low	$5.65
52-week low date	2026-04-13
5Y price change	16.35%
5Y return CAGR	3.08%
5Y total return	16.35%
6M price change	53.72%
6M total return	53.72%
All-time high	$124.20
All-time high date	2004-11-24
All-time low	$0.30
All-time low date	2012-08-29
Average true range (ATR)	$0.48
Average volume	115.8K
Beta (1Y)	1.92
Beta (2Y)	1.69
Beta (5Y)	1.23
Change from 52-week high	-20.53%
Change from 52-week low	86.37%
Change from all-time high	-91.52%
Change from all-time low	3,410%
Change from open	0.38%
Day's gap	-1.22%
Dollar volume	$1.1M
High price	$10.53
Low price	$10.49
Monthly RSI	56.78
Open price	$10.49
Position in 52-week range	100%
Previous close	$10.62
Price vs 150-day SMA	9.58%
Price vs 20-day SMA	1.63%
Price vs 200-day SMA	14.78%
Price vs 50-day SMA	-3.99%
Relative volume	0.94
RSI	50.3
Sharpe ratio	0.52
Sharpe ratio (3Y)	0.47
Sharpe ratio (5Y)	0.3
Sortino ratio	0.98
Sortino ratio (3Y)	0.82
Sortino ratio (5Y)	0.52
Volume	106.8K
Weekly RSI	53.52
YTD price change	36.75%
YTD total return	36.75%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	19.8M
Float percentage	56.6%
Shares change (QoQ)	2.48%
Shares change (YoY)	16.69%
Shares held by insiders	2.97%
Shares held by institutions	26.28%
Shares outstanding	35.1M
Short % of float	2.59%
Short % of shares	1.46%
Short ratio	2.5 days

Deeper analysis on FENC

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this FENC report

Is a complete FENC research report available?

No complete published report is available for Fennec Pharmaceuticals Inc. (FENC) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Fennec Pharmaceuticals Inc. (FENC)

Price

Financial snapshot

Fair-value bridge

Latest news · FENC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All FENC indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on FENC

Frequently asked questions